Projects
HSAFE 101232577
The HSAFE project aims to revolutionize early cancer detection by developing an ultra-sensitive biosensor for identifying lymphoma and lung cancers at their earliest stages.
Marie Skłodowska-Curie Actions Staff Exchange (SE) Call: HORIZON-MSCA-2024-SE-01
HSAFE 101232577
Innovative high-sensitivity avalanche field-effect transistors designed for cancer diagnosis
Coordinator: Ayşegül Kahmaran, BUU (TR)
Starting/Ending date: 01 September, 2025 - 31 August, 2029
Duration: 48 months
Budget: € 1 618 230,00
Partners
- Bursa Uludağ University - BUU, Turkey
- IST Microeletronics - IST, Turkey
- Minds in Motion Foundation - MIMF, Hungary
- V.Ye. Lashkaryov Institute of Semiconductor Physics – ISP, Ukraine
- Associação DeepTechLab – DTL, Portugal
- Nanomaterials Research & Development – NRD, Poland
- SETM – Center for Scientific Strategic Research – SETM, Azerbaijan
- Institute of Radiation Problems - IRP, Azerbaijan
SUMMARY
The HSAFE project aims to revolutionize early cancer detection by developing an ultra-sensitive biosensor for identifying lymphoma and lung cancers at their earliest stages. Today, these diseases are often diagnosed too late, when treatment is less effective and patient outcomes are poorer. By integrating avalanche transistor electronics, smart transducer materials, and nanoparticle (Au-NP) enhancements, the project seeks to create a device capable of detecting tiny traces of cancer-related miRNA biomarkers far earlier than current technologies allow. With reduced graphene oxide (rGO) and MoS₂ layers designed for high biomarker affinity, the biosensor aspires to set a new standard in accuracy, speed, and reliability for non-invasive cancer diagnostics.
The vision behind HSAFE is to deliver a tool that is not only scientifically advanced but also portable, cost-effective, and widely accessible. If successful, the biosensor could enable earlier intervention, more precise monitoring of disease progression, and pave the way for personalized treatment strategies that improve survival rates and quality of life. In doing so, HSAFE aligns with Europe’s Beating Cancer Plan and the broader goals of the European Health Union, reinforcing the EU’s commitment to boosting early detection and ensuring equitable access to healthcare innovation.
Spearheaded by a consortium of leading European universities, research institutions, and SMEs—together with partners from Associated and Partner Countries—the project brings together expertise in semiconductors, nanomaterials, biomedical engineering, and oncology. This collaboration is designed to move the technology from concept to prototype while adhering to the highest European regulatory standards. By building strong foundations for future large-scale health initiatives under Horizon Europe and EU4Health, HSAFE aims to position Europe at the forefront of medical diagnostics and contribute to global efforts to transform cancer care.